Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Rises By 79.2%

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 333,600 shares, an increase of 79.2% from the October 31st total of 186,200 shares. Currently, 3.0% of the shares of the company are sold short. Based on an average daily volume of 143,500 shares, the days-to-cover ratio is presently 2.3 days.

ABVC BioPharma Price Performance

NASDAQ ABVC opened at $0.51 on Thursday. The firm has a market cap of $6.62 million, a P/E ratio of -0.59 and a beta of 0.82. The company’s 50 day moving average is $0.59 and its 200-day moving average is $0.71. ABVC BioPharma has a 12-month low of $0.41 and a 12-month high of $2.45.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.